文献速递泌尿男性生殖肿瘤

AMG 509(Xaluritamig):一种靶向STEAP1、具亲和力依赖性抗前列腺癌活性的XmAb 2+1 T细胞重定向免疫治疗药物

AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
PubMed 文献 · Cancer Discov · 2024-01-01

STEAP1在多数前列腺肿瘤中表达,并在转移性去势抵抗性前列腺癌(mCRPC)中表达升高,是潜在治疗靶点。研究开发了靶向STEAP1的XmAb 2+1 T细胞衔接器AMG 509(xaluritamig),体外可介导T细胞依赖性细胞毒作用,体内在前列腺癌异种移植和同系小鼠模型中促进肿瘤消退,亲和力驱动使其对高表达STEAP1的肿瘤细胞具有选择性。AMG 509是首个进入临床测试的STEAP1 T细胞衔接器,本文报告一例mCRPC患者经AMG 509治疗获得客观缓解的病例。

要点

  • AMG 509是首个进入临床测试的靶向STEAP1的XmAb 2+1 T细胞衔接器。
  • 体外介导T细胞依赖性细胞毒作用,体内在前列腺癌模型中促进肿瘤消退。
  • 亲和力驱动活性使其对高表达STEAP1的肿瘤细胞具有选择性。

核心结论

  • AMG 509提供了一种靶向免疫治疗途径,可调动患者T细胞杀伤表达STEAP1的肿瘤细胞,代表mCRPC的新治疗选择,并可能更广泛用于前列腺癌。

研究设计与样本

  • 本文为临床前研究并报告一例接受AMG 509治疗的mCRPC患者病例研究;AMG 509是首个进入临床测试的STEAP1 T细胞衔接器。

主要发现

  • AMG 509在体外介导对前列腺癌细胞系的有效T细胞依赖性细胞毒作用。
  • AMG 509在体内前列腺癌异种移植和同系小鼠模型中促进肿瘤消退。
  • 亲和力驱动的活性使AMG 509对高表达STEAP1的肿瘤细胞较正常细胞具有选择性。
  • 一例mCRPC患者在接受AMG 509治疗后获得客观缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in most prostate tumors and at increased levels in metastatic castration-resistant prostate cancer (mCRPC). We developed a STEAP1-targeted XmAb 2+1 T-cell engager (TCE) molecule, AMG 509 (also designated xaluritamig), that is designed to redirect T cells to kill prostate cancer cells that express STEAP1. AMG 509 mediates potent T cell-dependent cytotoxicity of prostate cancer cell lines in vitro and promotes tumor regression in xenograft and syngeneic mouse models of prostate cancer in vivo. The avidity-driven activity of AMG 509 enables selectivity for tumor cells with high STEAP1 expression compared with normal cells. AMG 509 is the first STEAP1 TCE to advance to clinical testing, and we report a case study of a patient with mCRPC who achieved an objective response on AMG 509 treatment. SIGNIFICANCE: Immunotherapy in prostate cancer has met with limited success due to the immunosuppressive microenvironment and lack of tumor-specific targets. AMG 509 provides a targeted immunotherapy approach to engage a patient's T cells to kill STEAP1-expressing tumor cells and represents a new treatment option for mCRPC and potentially more broadly for prostate cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Kelly et al., p. 76. This article is featured in Selected Articles from This Issue, p. 5.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Nolan-Stevaux O, Li C, Liang L, et al. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov. 2024. PMID: 37861452. doi:10.1158/2159-8290.CD-23-0984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。